https://www.selleckchem.com/pr....oducts/vevorisertib-
Neither excluding time in hospital from the as-treated analysis nor adjustment for factors affecting WCD compliance materially changed the results. No variable demonstrated a significant interaction in either the intention-to-treat or as-treated analysis. CONCLUSION Robust sensitivity analyses of as-treated and per-protocol analyses suggest that the WCD is protective in compliant patients with ejection fraction less than or equal to 35% during the first 3 months post-MI. © 2020 Wiley Periodicals, Inc.AIMS It is not
Like
Comment
Share
